Drugs / LYB002V14
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05928468 | Apr → Jul 2023 | COVID-19 | Guangzhou Patronus Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06167915 | Dec 2023 → Dec 2024 | Orthocoronavirinae infectious disease | Guangzhou Patronus Biotech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LYB002V14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05928468 ↗ |
| Modality | Vaccine | “The vaccine LYB002V14 was administered through intramuscular injection.” NCT05928468 ↗ |
| Route | Intramuscular | “administered through intramuscular injection” NCT05928468 ↗ |